Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07PMJ
|
||||
| Former ID |
DNC003653
|
||||
| Drug Name |
(+)-3-(1-Propyl-piperidin-3-yl)-phenol
|
||||
| Synonyms |
(-)3-(1-Propyl-piperidin-3-yl)-phenol
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [530310] | ||
| Formula |
C14H21NO
|
||||
| Canonical SMILES |
CCCN1CCCC(C1)C2=CC(=CC=C2)O
|
||||
| InChI |
1S/C14H21NO/c1-2-8-15-9-4-6-13(11-15)12-5-3-7-14(16)10-12/h3,5,7,10,13,16H,2,4,6,8-9,11H2,1H3
|
||||
| InChIKey |
HTSNFXAICLXZMA-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | D(3) dopamine receptor | Target Info | Inhibitor | [533938] | |
| D(2) dopamine receptor | Target Info | Inhibitor | [530310] | ||
| D(4) dopamine receptor | Target Info | Inhibitor | [533938] | ||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| WikiPathways | Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| GPCRs, OtherWP666:Hypothetical Network for Drug Addiction | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| Nicotine Activity on Dopaminergic NeuronsWP666:Hypothetical Network for Drug Addiction | |||||
| GPCRs, Other | |||||
| References | |||||
| Ref 530310 | J Med Chem. 1990 Jan;33(1):311-7.4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines: a novel class of compounds with central dopamine agonist properties. | ||||
| Ref 533938 | J Med Chem. 1993 Oct 15;36(21):3188-96.Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.